Community-acquired pneumonia in adults
Conditions
Interventions
Levofloxacin is given intravenously at 500mg/body for 3days. If the improvement is obtained, change from intravenous to oral intake.
Sponsors
Second Division, Department of Internal Medicine, Hamamatsu university school of medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Subjects are aged >= 18. 2.Subjects require treatment with intravenous antibiotics injection. 3.Patients who are diagnosed with community-acquired pneumonia including clinical findings listed below: 1)Fever (>=37 degrees Celsius), white blood cell count >9000/mm3, stab leucocytes >=15%, CRP >=0.5mg/dl. 2)Cough. Purulent sputum, Dyspnea, Chill, Chest pain, rales. 3)New infiltrative shadow on a chest X-ray
Exclusion criteria
Exclusion criteria: 1.Patients who took respiratory quinolones for current pneumonia. 2.Patients who are prohibited to take levofloxacin. 3.Patients with liver dysfunction AST:more than three times the upper limit of normal ALT:more than three times the upper limit of normal T-bil:more than three times the upper limit of normal 4.Patients witg renal dysfunction (Cre is over than 3.0mg/dl, or Ccr is less than 30 mL/min/1.73m2) 5.Patients who has disease of central nervous system and expected spasm. 6.Patient whom conducting of the examination doctor judged inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical effectiveness at seven days after the end of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical and bacteriological effectiveness at the end of treatment. mortality, hospitalization, adverse event. | — |
Countries
Japan
Contacts
Public ContactYasuomi Satake
Hamamatsu University School of Medicine Second division,Department of Internal Medicine
Outcome results
None listed